Altamira Therapeutics (CYTO) Scheduled to Post Earnings on Tuesday

Altamira Therapeutics (NASDAQ:CYTOGet Free Report) will be releasing its earnings data before the market opens on Tuesday, September 12th. Persons interested in registering for the company’s earnings conference call can do so using this link.

Altamira Therapeutics Trading Down 2.5 %

Shares of CYTO stock opened at $0.33 on Friday. Altamira Therapeutics has a 12 month low of $0.31 and a 12 month high of $13.52. The business’s 50 day moving average is $0.39 and its two-hundred day moving average is $0.93.

Hedge Funds Weigh In On Altamira Therapeutics

An institutional investor recently bought a new position in Altamira Therapeutics stock. Citadel Advisors LLC acquired a new position in Altamira Therapeutics Ltd. (NASDAQ:CYTOFree Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 72,931 shares of the company’s stock, valued at approximately $47,000. Citadel Advisors LLC owned about 1.04% of Altamira Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.33% of the company’s stock.

Altamira Therapeutics Company Profile

(Get Free Report)

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells.

See Also

Earnings History for Altamira Therapeutics (NASDAQ:CYTO)

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with's FREE daily email newsletter.